Following the cardiovascular outcome trials (CVOTs) of SGLT2 inhibitors, these drugs were serendipitously shown to confer a reduction of HF events among T2DM patients, a finding that was independent of their glucose-lowering effect. Here, SLC5A2 is linked to type 2 diabetes mellitus.